SINOVAC agrees to supply an additional 101,000 doses of COVID-19 vaccines (CoronaVac®) to meet demand for inactivated virus vaccines from Singapore residents

· Doses will be available through SGX-Catalist listed Livingstone Health group at 17 clinics islandwide

· Inactivated viral vaccines offer an alternative option for those unable to take up vaccines available under the National Vaccine Programme, or prefer inactivated virus vaccines

Singapore, 15 September 2021: SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company") is fulfilling demand from Singapore residents for inactivated COVID-19 vaccines with an additional 101,000 doses of the inactivated COVID-19 vaccine (CoronaVac® ), arriving in Singapore on 20^th Sept 2021. The doses will be available through healthcare group Livingstone Health Holding Limited (SGX: PRH) (“Livingstone Health”).

From 24th September 2021, the vaccines will be available at four clinics under Livingstone Health's primary healthcare arm Phoenix Medical as well as at Ardennes Health Screening and Radiology Centre. Advanced booking is required and can be made from 17th September 2021 at these clinics. The vaccines will also be available at 13 other primary care clinics islandwide (see Annex A for the full list of clinics currently offering the vaccine).

"We are incredibly proud to be part of the important drive to vaccinate as many people as possible in Singapore in the fight against COVID-19. With the latest real-world data showing strong results and safety profile for the SINOVAC vaccine, both in terms of prevention of COVID-19 infection and reduction in hospitalisation and mortality, we encourage all residents who prefer inactivated virus vaccines or have opted not to get vaccinated yet, to make an appointment for vaccination as soon as possible to protect themselves and the broader community," said Dr. Chua Hshan Cher, Head of Primary Care, Livingstone Health.

Singapore's Ministry of Health announced in August that its stock of CoronaVac® would be depleted after ringfencing sufficient supplies for those receiving their second doses, and that it would facilitate the ordering of more doses by private healthcare institutions. The Ministry had earlier procured 200,000 doses of the vaccine, of which 170,000 were made available to the public at primary care clinics under the Special Access Route framework.

"SINOVAC is committed to ensuring access to safe and effective vaccines, through strong partnerships with governments and healthcare providers, in the fight against COVID-19. This second delivery of 101,000 CoronaVac® doses to Singapore reflects the close working relationships that we have established with essential stakeholders in the country. We will continue to pursue such strategic collaborations to help countries move to post-pandemic recovery as soon as possible," said Liu Peicheng, spokesperson for SINOVAC.

New data demonstrate safety and efficacy of CoronaVac®, including against the Delta variant

The latest data on CoronaVac®, released in September 2021, indicate that a booster dose of the vaccine can elicit fast and long lasting humoral immune response and effectively neutralise against the Delta variant[1]. Real-world evidence from Chile published in July also showed that CoronaVac® is safe and offers effective protection against COVID-19[2]. The study was conducted by the Chile Ministry of Health with a cohort of 10.2 million persons — one of the largest COVID-19 efficacy study in the world to date, with the biggest sample size. The study found that CoronaVac® was 65.9% effective at preventing COVID-19 and 87.5% effective at preventing hospitalisation. Additionally, the vaccine was 90.3% effective at preventing Intensive Care Unit (ICU) admission and 86.3% effective at preventing COVID-19 related death. Another real-world safety study[3] conducted in Chile comparing CoronaVac® to an mRNA vaccine control group, found that CoronaVac® has a better safety profile, with a lower rate of adverse and serious adverse reactions. The study showed that the safety of CoronaVac® is far better than the control group, which had an incidence rate of adverse reactions that was 15 times higher than CoronaVac®. The incidence of serious adverse reactions is approximately four times that of CoronaVac®.

By the end of August 2021, CoronaVac® had been approved for emergency use by local drug regulatory authorities in nearly 50 countries and regions, including Singapore. The total supply has already exceeded 1.8 billion doses, with an estimated 1.4 billion doses already administrated worldwide. SINOVAC has become the largest domestic supplier and exporter of China’s COVID-19 vaccine. The safety and effectiveness of CoronaVac® has been verified around the world.

[1] A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. https://doi.org/10.1101/2021.09.02.21261735    

[2] Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. https://www.nejm.org/doi/full/10.1056/NEJMoa2107715

[3] Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine by SAGE. https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf

About SINOVAC

SINOVAC Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialisation of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent pneumococcal polysaccharide ("PPV"), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella and mumps.

SINOVAC's COVID-19 vaccine, CoronaVac®, has been granted emergency use approval or conditional marketing authorisation by over 50 countries or regions worldwide. Healive®, the hepatitis A vaccine manufactured by the Company, passed WHO prequalification assessment in 2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease, was commercialised in China in 2016. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese government's vaccination campaign and stockpiling programme. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling programme. The Company is developing several new products including a Sabin-strain inactivated polio vaccine and combined vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorisation of its products in over 30 countries worldwide. For more information, please visit the Company's website at www.sinovac.com.

Media Contact

Jean Angus

Sandpiper Communications

jean.angus@sandpipercomms.com

Annex A: List of participating clinics offering additional CoronaVac®